

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司 \***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

## **VOLUNTARY ANNOUNCEMENT RESEARCH AND DEVELOPMENT UPDATE**

Reference is made to the voluntary announcements of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 28 October 2016, 14 May 2017, 6 June 2017, 1 November 2018, 4 December 2018, 16 April 2019, 7 November 2019, 8 December 2019 and 9 December 2019.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that Legend Biotech Corporation, a subsidiary of the Company, will present the new and updated data on CARTITUDE-1 and LEGEND-2 studies at the 62nd American Society of Hematology (“**ASH**”) Annual Meeting and Exposition taking place virtually from December 5 to 8, 2020. For details, please visit the 62nd ASH Annual Meeting’s website at <https://www.hematology.org/meetings/annual-meeting/schedule-and-program>.

Abstracts of the data from the above studies will be presented during the following dates and times. Certain updated data for CARTITUDE-1 will be presented during the oral presentation which will highlight Phase 1b/2 efficacy and safety results for the B-cell maturation antigen (“**BCMA**”) -targeted chimeric antigen receptor T cell (“**CAR-T**”) therapy ciltacabtagene autoleucel (“**cilta-cel**”).

Study	Abstract#/Title	Date and Time
<b>CARTITUDE-1</b> (MMY2001, NCT03548207, United States and Japan)	<b>Abstract #177:</b> CARTITUDE-1: Phase 1b/2 Study of cilta-cel, a B-cell Maturation Antigen — Directed CAR-T Therapy, in Relapsed/Refractory Multiple Myeloma	<b>Oral Presentation</b>  Saturday, December 5 12:00 p.m. (Pacific Time) (“PT”)
	<b>Abstract #1412:</b> Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of cilta-cel in Relapsed/ Refractory Multiple Myeloma	<b>Poster Presentation</b>  Saturday, December 5 7:00 a.m.–3:30 p.m. PT
	<b>Abstract #2291:</b> Health-Related Quality of Life in the CARTITUDE-1 Study of cilta-cel for Relapsed/Refractory Multiple Myeloma	<b>Poster Presentation</b>  Sunday, December 6 7:00 a.m.–3:30 p.m. PT
	<b>Abstract #3240:</b> Cytokine Release Syndrome in Patients With Relapsed/Refractory Multiple Myeloma Treated With cilta-cel in the Phase 1b/2 CARTITUDE-1 Study	<b>Poster Presentation</b>  Monday, December 7 7:00 a.m.–3:30 p.m. PT
<b>LEGEND-2</b> (NCT03090659), China	Abstract #2304: CAR-T Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease — a Single Institution Observation in China (LEGEND-2)	<b>Poster Presentation</b>  Sunday, December 6 7:00 a.m.–3:30 p.m. PT

## About CARTITUDE-1

Cilta-cel is currently being investigated in the Phase 1b/2 CARTITUDE-1 (MMY2001, NCT03548207) registration study conducted in the United States and Japan for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy or are double refractory to a protease inhibitor (“PI”) and immunomodulatory drug (“IMiD”), received a PI, an IMiD, and anti-CD38 antibody and documented disease progression within 12 months of starting the most recent therapy.

## About LEGEND-2

LEGEND-2 (NCT03090659) is an ongoing single-arm, open-label Phase 1 study of 74 patients being conducted at four participating hospitals in China evaluating the efficacy and safety of LCAR-B38M CAR-T cells for the treatment of relapsed or refractory multiple myeloma.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.**

By order of the Board  
**Genscript Biotech Corporation**  
**Wang Ye**  
*Executive Director*

Hong Kong, 5 November 2020

*As at the date of this announcement, the executive Directors are Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.*

\* *For identification purposes only*